Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

GlobeNewswireOct 30 08:30 ET

HC Wainwright & Co. Reiterates Buy on Allogene Therapeutics, Maintains $9 Price Target

Analyst UpgradesOct 30 08:29 ET

Allogene Receives FDA RMAT Designation for Its Metastatic Renal Cell Carcinoma Treatment

Seeking AlphaOct 29 09:24 ET

Express News | Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Allo-316, an Allocar T™ Investigational Product for Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (Rcc)

ReutersOct 29 08:30 ET

Express News | Artiva Biotherapeutics Appoints Alison Moore, Ph.d., to Its Board of Directors

ReutersOct 22 16:05 ET

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

GlobeNewswireOct 22 16:05 ET